Adcirca News and Research RSS Feed - Adcirca News and Research

Adcirca is a once-daily phosophodiesterase-5 (PDE-5) inhibitor for Pulmonary Arterial Hypertension (PAH) (WHO Group I) that improves your ability to exercise.
FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

FDA approves OLYSIO (simeprevir) for treatment of chronic hepatitis C infection

Janssen Therapeutics, Division of Janssen Products, LP, announced today the U.S. Food and Drug Administration has approved OLYSIO (simeprevir), an NS3/4A protease inhibitor, for the treatment of chronic hepatitis C infection as part of an antiviral treatment regimen in combination with pegylated interferon and ribavirin in genotype 1 infected adults with compensated liver disease, including cirrhosis. [More]

Data from MK-5172 Phase II study for treatment of HCV genotype 1 infection to be presented at EASL meeting

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of the latest interim data from a Phase II, multi-center, randomized, dose-ranging clinical trial evaluating the safety and antiviral activity of MK-5172, for the treatment of chronic hepatitis C virus genotype 1 infection. [More]

New data on Merck’s VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting. [More]
Study shows co-administration of Cialis, finasteride meets primary endpoint in men with LUTS/BPH

Study shows co-administration of Cialis, finasteride meets primary endpoint in men with LUTS/BPH

Eli Lilly and Company presented results today at the annual European Association of Urology Congress in Milan, Italy, of a study that showed Cialis 5 mg once daily co-administered with finasteride significantly improved scores on the International Prostate Symptom Score, compared to placebo/finasteride, in men with lower urinary tract symptoms of benign prostatic hyperplasia and enlarged prostates. [More]
Tadalafil may offer therapeutic strategy in patients with Becker muscular dystrophy

Tadalafil may offer therapeutic strategy in patients with Becker muscular dystrophy

Cedars-Sinai Heart Institute researchers have found in an initial clinical trial that a drug typically prescribed for erectile dysfunction or pulmonary hypertension restores blood flow to oxygen-starved muscles in patients with a type of muscular dystrophy that affects males, typically starting in childhood or adolescence. [More]
Lilly receives EC approval for Cialis to treat benign prostatic hyperplasia

Lilly receives EC approval for Cialis to treat benign prostatic hyperplasia

Eli Lilly and Company announced today that the European Commission has approved Cialis 5 mg for once daily use for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH). [More]
Synthon receives tentative approval for tadalafil tablets

Synthon receives tentative approval for tadalafil tablets

Synthon has announced that its subsidiary Synthon Pharmaceuticals, Inc. has received tentative approval from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug application for tadalafil tablets, 20 mg on April 13, 2012. Synthon's product is a generic and bioequivalent version of Eli Lilly & Co and United Therapeutics’ Adcirca® tablets, which are indicated for the treatment of pulmonary arterial hypertension to improve exercise ability. [More]
New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

New analyses from Phase III studies of VICTRELIS to be presented at AASLD 2011

Merck, known as MSD outside of the United States and Canada, announced today that several new analyses from Phase III studies of VICTRELIS (boceprevir), the company's first-in-class, oral hepatitis C virus NS3/4A protease inhibitor will be presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases. [More]

Roche, Merck sign new non-exclusive agreement for HCV triple combination therapy

Merck, known as MSD outside the United States and Canada, announced today that it has signed a new non-exclusive agreement with Roche, through the companies' respective subsidiaries, for the global promotion, upon appropriate marketing approvals, of VICTRELIS (boceprevir) as part of a triple combination therapy regimen with peginterferon alfa and ribavirin. [More]
Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex receives FDA approval for INCIVEK to treat hepatitis C

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has approved INCIVEK™ (telaprevir) tablets for a broad group of people with genotype 1 chronic hepatitis C with compensated liver disease (some level of damage to the liver but the liver still functions), including cirrhosis (scarring of the liver). [More]
Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck's VICTRELIS receives European CHMP positive opinion for treatment of chronic HCV genotype 1 infection

Merck, today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion under accelerated assessment recommending approval of the investigational medicine VICTRELIS (boceprevir) for the treatment of chronic hepatitis C virus genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy. [More]
Tadalafil improves Raynaud's phenomenon symptoms in people with scleroderma

Tadalafil improves Raynaud's phenomenon symptoms in people with scleroderma

Adding tadalafil (Cialis®; Adcirca®) to the treatment of people with scleroderma can improve Raynaud's phenomenon symptoms and heal and prevent hand and finger ulcers associated with it, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Atlanta. [More]

United Therapeutics third quarter total revenues increase to $171.0 million

United Therapeutics Corporation today announced its results of operations for the quarter ended September 30, 2010. [More]

United Therapeutics second-quarter total revenues increase to $137.5 million

United Therapeutics Corporation today announced its results of operations for the quarter ended June 30, 2010. [More]
Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study. [More]

Report on key trends shaping and driving global PAH market

GlobalData's report, "Pulmonary Arterial Hypertension (PAH) – Pipeline Assessment and Market Forecasts to 2016" provides an essential source of information and analysis on the global PAH market. The report identifies the key trends shaping and driving the global PAH market. [More]
United Therapeutics launches support program for PAH patients

United Therapeutics launches support program for PAH patients

United Therapeutics Corporation and Lung Rx, LLC announced today the launch of a nationwide support program for patients who are currently prescribed a United Therapeutics therapy, which includes Remodulin (treprostinil) Injection, Adcirca (tadalafil) tablets or Tyvaso (treprostinil) Inhalation Solution. [More]

United Therapeutics reports strong revenue growth in first quarter 2010

United Therapeutics Corporation today announced its results of operations for the quarter ended March 31, 2010. [More]

Adcirca now available in Canada for treatment of pulmonary arterial hypertension

Adcirca(TM) (tadalafil) is now available in Canada for the treatment of pulmonary arterial hypertension (PAH). Adcirca represents an important new and convenient option for the estimated 2,000 to 10,000 Canadians with this rare but progressive and serious disorder. [More]
Eli Lilly provides financial guidance for 2010

Eli Lilly provides financial guidance for 2010

At its annual meeting today with the investment community, Eli Lilly and Company highlighted how its innovation-based strategy will enable it to better serve patients and compete effectively in a challenging health care environment. The company also detailed the progress being made in its labs and across its five new business units on an expanding pipeline of innovative molecules and marketed medicines, and provided investors with the company's financial guidance for 2010. [More]